{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:30:38Z","timestamp":1789165838420,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00417-021-05246-5","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T09:03:11Z","timestamp":1629450191000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections"],"prefix":"10.1007","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1694-405X","authenticated-orcid":false,"given":"Tatiana R.","family":"Rosenblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Rayess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Moujahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-9736","authenticated-orcid":false,"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"3","key":"5246_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ajo.2013.11.012","volume":"157","author":"P Mitchell","year":"2014","unstructured":"Mitchell P, Wong T, Diabetic Macular Edema Treatment Guideline Working Group (2014) Management paradigms for diabetic macular edema. Am J Ophthalmol 157(3):505\u2013513","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"5246_CR2","first-page":"1751","volume":"123","author":"M Maguire","year":"2016","unstructured":"Maguire M, Martin DF, Ying G-S et al (2016) Neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatment trials. J Ophthalmol 123(8):1751\u20131761","journal-title":"J Ophthalmol"},{"issue":"8","key":"5246_CR3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ophtha.2018.03.046","volume":"125","author":"JF Payne","year":"2018","unstructured":"Payne JF, Clark WL, Bruce BB et al (2018) Retinopathy regression with treat and extend ranibizumab for diabetic macular edema. Ophthalmology 125(8):1304\u20131306. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.046","journal-title":"Ophthalmology"},{"key":"5246_CR4","volume-title":"Age-related macular degeneration: prevalence, risk factors, and clinical management","author":"M Carter","year":"2015","unstructured":"Carter M (2015) Age-related macular degeneration: prevalence, risk factors, and clinical management. Nova Sciences Publisher, Inc., New York"},{"issue":"1","key":"5246_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C (2015) Epidemiology of diabetic retinopathy, diabetic macular edema, and related vision loss. Eye Vis 2(1):1\u201325. https:\/\/doi.org\/10.1186\/s40662-015-0026-2","journal-title":"Eye Vis"},{"issue":"2","key":"5246_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313\u2013320. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"issue":"14","key":"5246_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432\u20131444","journal-title":"N Engl J Med"},{"issue":"14","key":"5246_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"P Rosenfeld","year":"2006","unstructured":"Rosenfeld P, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431","journal-title":"N Engl J Med"},{"issue":"5","key":"5246_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L et al (2016) Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 36(5):859\u2013867","journal-title":"Retina"},{"issue":"4","key":"5246_CR10","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ophtha.2020.01.029","volume":"127","author":"DF Martin","year":"2020","unstructured":"Martin DF, Maguire MG, Fine SL et al (2020) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 127(4):S135\u2013S145","journal-title":"Ophthalmology"},{"issue":"8","key":"5246_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","volume":"138","author":"M Ramakrishnan","year":"2020","unstructured":"Ramakrishnan M, Yu Y, VanderBeek B (2020) Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the Comparison of Age-related Macular Degeneration Treatment Trial. JAMA Ophthalmol 138(8):237\u2013242","journal-title":"JAMA Ophthalmol"},{"key":"5246_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"J Kim","year":"2017","unstructured":"Kim J, Chang J, Kim J (2017) Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 37:2254\u20132261","journal-title":"Retina"},{"issue":"3","key":"5246_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","volume":"126","author":"A Obeid","year":"2019","unstructured":"Obeid A, Su D, Patel SN et al (2019) Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology 126(3):407\u2013413","journal-title":"Ophthalmology"},{"key":"5246_CR14","doi-asserted-by":"publisher","first-page":"7691724","DOI":"10.1155\/2020\/7691724","volume":"2020","author":"H Abdelmotaal","year":"2020","unstructured":"Abdelmotaal H, Ibrahim W, Sharaf M, Abdelazeem K (2020) Causes and clinical impact of loss to follow-up in patients with proliferative diabetic retinopathy. J Ophthalmol 2020:7691724","journal-title":"J Ophthalmol"},{"key":"5246_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","volume":"204","author":"T Wubben","year":"2019","unstructured":"Wubben T, Johnson M, The Anti-VEGF Treatment Interruption Study Group (2019) Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 204:13\u201318","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"5246_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"A Khanani","year":"2020","unstructured":"Khanani A, Skelly A, Bezlyak V et al (2020) SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retin 4(2):122\u2013133","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"5246_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, Inan S, Ozcan S et al (2017) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol 47(4):205\u2013210","journal-title":"Turk J Ophthalmol"},{"issue":"2","key":"5246_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K et al (2018) Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23(2):127\u2013140","journal-title":"Psychol Health Med"},{"issue":"9","key":"5246_CR19","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","volume":"34","author":"A Vaze","year":"2014","unstructured":"Vaze A, Fraser-Bell S, Gillies M (2014) Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. Retina 34(9):1774\u20131778","journal-title":"Retina"},{"key":"5246_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","volume":"251","author":"K Droege","year":"2013","unstructured":"Droege K, Muether PS, Hermann MM et al (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281\u20131284","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5246_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2019.10.012","volume":"210","author":"B Zhou","year":"2020","unstructured":"Zhou B, Mitchell T, Rusakevich A et al (2020) Noncompliance in prospective retina clinical trials: analysis of factors predicting loss to follow-up. Am J Ophthalmol 210:86\u201396","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"5246_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.2106\/JBJS.16.00900","volume":"99","author":"K Madden","year":"2017","unstructured":"Madden K, Scott T, McKay P et al (2017) Predicting and preventing loss to follow-up of adult trauma patients in randomized controlled trials: an example from the FLOW trial. J Bone Jt Surg Am 99(13):1086\u20131092","journal-title":"J Bone Jt Surg Am"},{"key":"5246_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3928\/23258160-20190301-05","volume":"50","author":"X Gao","year":"2019","unstructured":"Gao X, Obeid A, Adam M, Hyman L et al (2019) Loss to follow-up in patients with retinal vein occlusion undergoing intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging Retin 50:159\u2013166","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"9","key":"5246_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","volume":"125","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 125(9):1386\u20131392","journal-title":"Ophthalmology"},{"issue":"3","key":"5246_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","volume":"3","author":"X Gao","year":"2019","unstructured":"Gao X, Obeid A, Aderman CM et al (2019) Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema. Ophthalmol Retin 3(3):230\u2013236","journal-title":"Ophthalmol Retin"},{"issue":"10","key":"5246_CR26","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00417-019-04414-y","volume":"257","author":"R Angermann","year":"2019","unstructured":"Angermann R, Rauchegger T, Nowosielski Y et al (2019) Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol 257(10):2119\u20132125","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"5246_CR27","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal antivascular endothelial growth factor injections. JAMA Ophthalmol 136(11):1251\u20131259","journal-title":"JAMA Ophthalmol"},{"key":"5246_CR28","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38:2293\u20132300","journal-title":"Retina"},{"key":"5246_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ajo.2020.03.011","volume":"215","author":"R Suresh","year":"2020","unstructured":"Suresh R, Yu HJ, Thoveson A et al (2020) Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice. Am J Ophthalmol 215:66\u201371","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"5246_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1503\/cjs.006314","volume":"57","author":"M Kaur","year":"2014","unstructured":"Kaur M, Sprague S, Ignacy T et al (2014) How to optimize patient retention and complete follow-up in surgical research. Can J Surg 57(6):420\u2013427","journal-title":"Can J Surg"},{"issue":"2","key":"5246_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/1740774514562031","volume":"12","author":"CJ Sellers","year":"2015","unstructured":"Sellers CJ, Lee H, Chasela C et al (2015) Reducing lost to follow-up in a large clinical trial of prevention of mother-to-child transmission of HIV: the breastfeeding, antiretrovirals and nutrition (BAN) study experience. Clin Trials 12(2):156\u2013165. https:\/\/doi.org\/10.1177\/1740774514562031","journal-title":"Clin Trials"},{"key":"5246_CR32","doi-asserted-by":"crossref","unstructured":"Norvell DC, Dettori JR, and Chapman JR (2016) Enhancing clinical study retention rates to avoid follow-up bias: how do we keep our study participants from \u2018The Land of the Lost\u2019? Glob Spine J 6(5):519\u2013521","DOI":"10.1055\/s-0036-1584928"},{"key":"5246_CR33","first-page":"19","volume":"10","author":"SJ Fudemberg","year":"2016","unstructured":"Fudemberg SJ, Lee B, Waisbourd M et al (2016) Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic. Patient Prefer Adherence 10:19\u201325","journal-title":"Patient Prefer Adherence"},{"issue":"92","key":"5246_CR34","first-page":"68","volume":"28","author":"K Lewis","year":"2015","unstructured":"Lewis K (2015) Improving patient compliance with diabetic retinopathy screening and treatment. Community Eye Heal 28(92):68\u201369","journal-title":"Community Eye Heal"},{"issue":"10","key":"5246_CR35","doi-asserted-by":"publisher","first-page":"P1331","DOI":"10.1016\/j.ophtha.2020.03.035","volume":"127","author":"D Kunimoto","year":"2020","unstructured":"Kunimoto D, Yoon YH, Wykoff CC et al (2020) Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology 127(10):P1331\u2013P1344","journal-title":"Ophthalmology"},{"issue":"9","key":"5246_CR36","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ et al (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138(9):964\u2013972. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"5246_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ncb1715","volume":"138","author":"I De La Huerta","year":"2020","unstructured":"De La Huerta I, Kim SJ, Sternberg P (2020) Faricimab combination therapy for sustained efficacy in neovascular age-related macular degeneration. JAMA Ophthalmol 138(9):972\u2013973. https:\/\/doi.org\/10.1038\/ncb1715","journal-title":"JAMA Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05246-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:26:33Z","timestamp":1642515993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05246-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5246"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05246-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Stanford University Institutional Review Board determined that this study was exempt from requiring IRB approval as it does not meet the definition of human subject research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}